title: Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory.
abstract: Statins are some of the most commonly prescribed drugs and are used to reduce blood cholesterol. Recent evidence suggests that, in some patients, they may adversely influence cognitive function including causing memory impairments. These clinical observations have led to statin prescriptions now including a warning about possible cognitive impairments. In order to better understand the relationship between statin treatment and cognitive function, studies in animals are needed. The present study investigated the effects of chronic treatment with two statins, pravastatin and atorvastatin, in two rodent models of learning and memory. Adult rats were treated once daily with pravastatin (10 mg/kg, orally) or atorvostatin (10 mg/kg, orally) for 18 days. Before, during and after treatment, animals were tested in a simple discrimination and reversal learning task. On the last day of treatment and following one week withdrawal, animals were also tested in a task of novel object discrimination. Pravastatin tended to impair learning over the last few days of treatment and this effect was fully reversed once treatment ceased. In the novel object discrimination task, pravastatin significantly impaired object recognition memory. No effects were observed for atorvostatin in either task. These data suggest that chronic treatment with pravastatin impairs working and recognition memory in rodents. The reversibility of the effects on cessation of treatment is similar to what has been observed in patients, but the lack of effect of atorvostatin suggests that lipophilicity may not be a major factor influencing statin-induced cognitive impairments.
authors.affiliation: School of Physiology and Pharmacology, University of Bristol, Bristol, United Kingdom.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Stuart
authors.forename: James D
authors.initials: JD
authors.lastname: Robertson
authors.forename: Neil V
authors.initials: NV
authors.lastname: Marrion
authors.forename: Emma S J
authors.initials: ES
authors.lastname: Robinson
mesh_terms: D000818:Animals; D000069059:Atorvastatin; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003071:Cognition / Q000187:drug effects* / Q000502:physiology*; D004192:Discrimination, Psychological / Q000187:drug effects; D006538:Heptanoic Acids / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D008568:Memory / Q000187:drug effects*; D017035:Pravastatin / Q000009:adverse effects* / Q000494:pharmacology; D011758:Pyrroles / Q000009:adverse effects* / Q000494:pharmacology; D051381:Rats; D012193:Reversal Learning / Q000187:drug effects; D013997:Time Factors
chemical_list: D006538:Heptanoic Acids; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin; D017035:Pravastatin
references.citation: J Neurotrauma. 2008 Feb;25(2):130-9
references.pmid: 18260796
references.citation: Ann Pharmacother. 1995 Jul-Aug;29(7-8):743-59
references.pmid: 8520093
references.citation: Arch Neurol. 2000 Oct;57(10):1439-43
references.pmid: 11030795
references.citation: Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9
references.pmid: 11701455
references.citation: Clin Neuropharmacol. 1991 Jun;14(3):256-61
references.pmid: 1906375
references.citation: J Neurotrauma. 2007 Jul;24(7):1132-46
references.pmid: 17610353
references.citation: J Neurosci. 2004 Jun 30;24(26):5901-8
references.pmid: 15229237
references.citation: Neurology. 2002 Oct 22;59(8):1257-8
references.pmid: 12391360
references.citation: Steroids. 2004 Jun;69(6):431-8
references.pmid: 15219793
references.citation: Drugs. 2001;61(2):197-206
references.pmid: 11270938
references.citation: Am J Cardiol. 2001 Mar 8;87(5A):28B-32B
references.pmid: 11256847
references.citation: Pharmacotherapy. 2003 Dec;23(12):1663-7
references.pmid: 14695047
references.citation: Genes Dev. 1997 Sep 15;11(18):2295-322
references.pmid: 9308960
references.citation: Ann Neurol. 2009 Sep;66(3):407-14
references.pmid: 19798641
references.citation: Behav Brain Res. 1986 Feb;19(2):133-46
references.pmid: 3964405
references.citation: Drugs. 1991 Jul;42(1):65-89
references.pmid: 1718686
references.citation: Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80
references.pmid: 12373437
references.citation: Neuroscience. 2010 Mar 17;166(2):435-44
references.pmid: 20040368
references.citation: Fundam Clin Pharmacol. 2005 Feb;19(1):117-25
references.pmid: 15660968
references.citation: Exp Neurol. 2007 Jul;206(1):59-69
references.pmid: 17521631
references.citation: Psychopharmacology (Berl). 2011 Aug;216(4):537-44
references.pmid: 21384104
references.citation: Behav Brain Res. 2007 Dec 28;185(2):82-7
references.pmid: 17804090
references.citation: Behav Brain Res. 1991 Apr 18;43(1):35-50
references.pmid: 1677579
references.citation: J Neurosci. 2000 Jun 1;20(11):4320-4
references.pmid: 10818167
references.citation: Lancet. 2000 Nov 11;356(9242):1627-31
references.pmid: 11089820
references.citation: Neurology. 2010 Mar 23;74(12):956-64
references.pmid: 20200346
references.citation: Pharmacotherapy. 2009 Jul;29(7):800-11
references.pmid: 19558254
references.citation: Eur J Immunol. 2006 Nov;36(11):2885-93
references.pmid: 17048274
references.citation: Pharmacotherapy. 2003 Jun;23(6):726-30
references.pmid: 12820814
references.citation: Prog Lipid Res. 2011 Oct;50(4):357-71
references.pmid: 21741992
references.citation: J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7
references.pmid: 18931004
references.citation: Psychopharmacology (Berl). 2005 May;179(2):336-48
references.pmid: 15645224
references.citation: Am J Cardiol. 1998 Mar 1;81(5):582-7
references.pmid: 9514454
references.citation: J Neurosci. 2007 Mar 14;27(11):2948-57
references.pmid: 17360918
references.citation: Am J Med. 2004 Dec 1;117(11):823-9
references.pmid: 15589485
references.citation: J Pharmacol Exp Ther. 1993 Dec;267(3):1085-90
references.pmid: 8263769
references.citation: Am Heart J. 2006 Feb;151(2):273-81
references.pmid: 16442888
references.citation: Neuron. 2003 Jun 19;38(6):987-96
references.pmid: 12818183
references.citation: J Pharmacol Exp Ther. 2006 Mar;316(3):1146-52
references.pmid: 16282522
references.citation: Br J Pharmacol. 2010 Aug;160(7):1577-9
references.pmid: 20649561
references.citation: Hippocampus. 2012 Mar;22(3):466-76
references.pmid: 21298728
references.citation: Lancet. 2002 Nov 23;360(9346):1623-30
references.pmid: 12457784
references.citation: Tohoku J Exp Med. 2008 Apr;214(4):341-9
references.pmid: 18441510
references.citation: Curr Opin Lipidol. 2001 Apr;12(2):105-12
references.pmid: 11264981
references.citation: Am J Cardiol. 2003 Mar 6;91(5A):11C-17C; discussion 17C-19C
references.pmid: 12646338
references.citation: Nature. 1997 Nov 20;390(6657):281-6
references.pmid: 9384379
references.citation: J Biol Chem. 1999 May 7;274(19):13675-80
references.pmid: 10224140
references.citation: J Pharmacol Exp Ther. 2005 Feb;312(2):786-93
references.pmid: 15358814
references.citation: Brain Res. 2011 Apr 22;1386:89-99
references.pmid: 21354117
references.citation: Mol Pharmacol. 2009 Dec;76(6):1279-89
references.pmid: 19726551
references.citation: Behav Brain Res. 1988 Nov 1;31(1):47-59
references.pmid: 3228475
references.citation: Neuropsychopharmacology. 2001 Jan;24(1):66-74
references.pmid: 11106877
references.citation: Eur J Pharmacol. 2004 Jan 12;483(2-3):133-8
references.pmid: 14729100
references.citation: Ann Pharmacother. 2006 Oct;40(10):1880-3
references.pmid: 16940411
references.citation: Tohoku J Exp Med. 2004 Dec;204(4):299-308
references.pmid: 15572855
references.citation: J Neurosci. 2003 Apr 15;23(8):3262-71
references.pmid: 12716933
references.citation: Expert Rev Cardiovasc Ther. 2003 Nov;1(4):495-505
references.pmid: 15030249
references.citation: Biochim Biophys Acta. 2003 Mar 10;1610(2):271-80
references.pmid: 12648780